REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

Clinical trial NCT05621148 · COMPLETED

Trial details

NCT number: NCT05621148
Sponsor: French Innovative Leukemia Organisation
Status: COMPLETED
Study type: OBSERVATIONAL

CLL, Relapsed CLL, Refractory Bruton Tyrosine Kinase Inhibitor Small Lymphocytic Leukemia

Start date: 2023-01-25
Primary completion: 2023-12-31
Enrollment: 152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.